Intermittent intravenous zoledronic acid increased bone mineral density in postmenopausal women

Evidence-based Obstetrics and Gynecology

Volumn 4, Issue 4, 2002, Pages 209-210

  Reid, I R ^b   Brown, J P ^b   Burckhardt, P ^b   Blank, Robert D ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; FLUORIDE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

AUSTRALIA; AUSTRIA; BELGIUM; BONE DENSITY; BONE MINERAL; CANADA; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FEMUR NECK; FRANCE; GERMANY; HUMAN; ITALY; LUMBAR SPINE; NEW ZEALAND; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SHORT SURVEY; SWEDEN; SWITZERLAND; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 3042693926     PISSN: 1361259X     EISSN: None     Source Type: Journal    
DOI: 10.1054/ebog.2002.0084     Document Type: Short Survey

References (3)

1. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-1259.
2. Cummings SR, Karpf DB, Harris F et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112: 281-289.
3. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-1936.